Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 219-223 , February 2010

Analysis of continuous patient data from the Czech National Register of patients with type 1 and type 2 diabetes using insulin pump therapy

  • Z. Jankovec

      Affiliations

    • Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
    • Corresponding Author InformationCorresponding author. Fax: +420 377 259 676.
    • ,
  • M. Hahn

      Affiliations

    • ArtiMed Medical Consulting GmbH, 34117 Kassel, Germany
    • ,
  • S. Grunder

      Affiliations

    • Disetronic AG, 3401 Burgdorf, Switzerland
    • ,
  • S. Lacigova

      Affiliations

    • Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
    • ,
  • D. Cechurova

      Affiliations

    • Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
    • ,
  • M. Krcma

      Affiliations

    • Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
    • ,
  • M. Zourek

      Affiliations

    • Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
    • ,
  • I. Haladova

      Affiliations

    • Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
    • ,
  • Z. Rusavy

      Affiliations

    • Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic

Received 13 May 2009 ,Revised 24 September 2009 ,Accepted 28 September 2009.

References 

  1. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ. 1978;1:204–207
  2. Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  3. Pfützner A, Berger S, Spinas G. Aktueller Stellenwert der kontinuierlichen subkutanen Insulininfusion (CSII) mit Insulinpumpen in der Therapie des Diabetes mellitus. Schweiz. Med. Wochenschr. 2000;130:1854–1861
  4. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol. Assess. 2004;8(43):
  5. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost effectiveness. Diabetes Metab. Res. Rev. 2004;20:178–188
  6. Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century. Postgrad. Med. 2002;111(5):69–77
  7. Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescent with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J. Pediatric Endocrinol. Metab. 2003;16:393–399
  8. Hissa MN, Hissa AS, Bruin VM, Fredrickson LP. Comparison between continuous subcutaneous insulin infusion and multiple insulin injection therapy in type 1 diabetes mellitus: 18-month follow-up. Endocr. Pract. 2002;8:411–416
  9. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years. Diabetes Care. 2002;25(3):593–598
  10. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab. Res. Rev. 2002;18(Suppl. 1):14–20
  11. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51(6):941–951
  12. Renard E. Intensive insulin therapy today: “basal-bolus” using multiple daily injections or CSII. Diabetes Metab. 2005;31(4):40–44
  13. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care. 2004;27:2590–2596
  14. Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, et al. Comparison of the effect of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin infusion (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabetic Med. 2005;23:141–147
  15. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705
  16. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy. A meta-analysis. Diabetes Care. 2003;26(4):1079–1087
  17. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51:941–951
  18. Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, et al. Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabetic Med. 2005;22:1037–1046
  19. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568–1573
  20. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598–2603
  21. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  22. Riveline JP, Jolloisb FX, Messaoudia N, Franca S, Lagardec F, Lormeau B, et al. Insulin-pump use in everyday practice: data from an exhaustive regional registry in France. Diabetes Metab. 2008;34:132–139
  23. Norgaard K. A nationwide study of continuous subcutaneous insulin infusion (CSII) in Denmark. Diabetes Med. 2003;20:307–311
  24. Tulokas T, Sane T, Niskanen L, Heikilla P, Nikkanen P, Huttunen M. Long term outcome of continuous subcutaneous insulin infusion on average of 8 years. Diabetes Metab. 2003;29(4):233
  25. Hammond P, Liebl A, Grunder S. International survey of insulin pump users: impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life. Prim. Care Diabetes. 2007;1(September (3)):143–146
  26. Jankovec Z, Cechurova D, Krcma M, Lacigova S, Zourek M, Rusavy Z, et al. National Register of patients with insulin pump treatment in the Czech Republic. Diab. Res. Clin. Pract. 2006;74:135–139
  27. Kapellen TM, Heidtmann B, Bachmann J, Ziegler R, Grabert M, Holl RW, et al. Indications for insulin pump therapy in different age groups-an analysis of 1567 children and adolescents. Diabetic Med. 2007;24:836–842
  28. Reda E, Von Reitzenstein A, Dunn P. Metabolic control with insulin pump therapy: the Waikato experience. NZMJ. 2007;120(1248):1–12

PII: S0168-8227(09)00420-3

doi: 10.1016/j.diabres.2009.09.028

Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 219-223 , February 2010

Article Tools

* Image Usage & Resolution